Study provides guidance on drug holidays from popular osteoporosis treatments

January 15, 2014

Doctors commonly recommend drug holidays, or breaks, from certain osteoporosis drugs due to the risks associated with these treatments. Yet little has been known about the ideal duration of the holidays and how best to manage patients during this time.

This popular class of medications, known as bisphosphonates, has been shown to cause fractures in the thigh bones and tissue decay in the . The American Association of Clinical Endocrinologists recommends a drug holiday or break from these treatments after four to five years of density stability if osteoporosis is moderate and after 10 years of stability if is high.

However, new research from Loyola University Health System reveals that should resume treatment if they develop a fracture, have a decline in bone strength or an early rise in signs indicative of increased fracture risk. Researchers also found that and those with very low bone strength should be closely followed during a break from treatment. These findings were published in the latest issue of Endocrine Practice.

"This study provides some guidance about what to do during drug holidays and how long they should last," said Pauline Camacho, MD, study investigator and director of the Loyola University Osteoporosis & Metabolic Bone Disease Center. "The results highlight groups who are at risk for fractures during drug holidays and recommendations on when to resume treatment."

Loyola researchers evaluated 209 patients who started a drug holiday from bisphosphonates. Eleven patients (5.2 percent) developed fractures and all patients had a significant increase in bone-specific alkaline phosphatase at six months. This level was more pronounced in patients who developed a fracture. While there was no significant change in the bone mineral density of the lumbar spine, there was a statistically significant decline in the femoral neck bone mineral density.

"These findings will help us continue to refine the current practice of drug holidays to better manage patients with osteoporosis," Dr. Camacho said.

Explore further: Osteoporosis drugs compared for side effects, efficacy

Related Stories

Osteoporosis drugs compared for side effects, efficacy

November 28, 2013
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...

Alendronate reduces adjacent-level vertebral fractures

December 30, 2013
(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue of Spine.

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

February 8, 2012
There is growing evidence that supports an association between atypical fractures of the femur– a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance ...

Not only bone density, but also quality of bone predicts fracture risk

August 5, 2013
In a study carried out at the University of Eastern Finland, bone histomorphometry and infrared spectroscopy revealed abnormal bone properties in children with vertebral fractures and in children after solid organ transplantation. ...

New IOF review provides guidance on fracture prevention in cancer-associated bone disease

November 1, 2013
Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies ...

Recommended for you

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.